Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

Hancom announces strategic investment in Spanish AI biometric company FacePhi


BARCELONA and SEOUL, South Korea, March 25, 2024 /PRNewswire/ -- Hancom (CEO Seong-jun Byun and Yeon-soo Kim) plans to make a strategic investment in FacePhi, a Spanish artificial intelligence (AI) biometric company.

Hancom's CEO Yeon-soo Kim (L) & FacePhi's CEO Javier Mira (R) at the Invest Signing Ceremony in Barcelona, Spain

Hancom announced on the 25th that it has signed an investment agreement in Barcelona, Spain, with Hancom's CEO Yeon-soo Kim and FacePhi's CEO Javier Mira in attendance. This investment agreement will allow Hancom to make equity investments in FacePhi and secure exclusive business rights to FacePhi in the APAC region.

Listed simultaneously on the Spanish and French stock exchanges, FacePhi holds various AI-based biometric technologies such as face, fingerprint, pupil, and voice recognition technologies required for biometric authentication. The company operates mainly in Europe and Latin America. Recognized for its excellent technology at home and abroad, it has secured a large number of financial companies as customers in Korea.

In particular, with regard to anti-spoofing (fake identification) functionality, which is the most important feature in facial recognition technology, FacePhi possesses technology using a passive method (authenticating identity with a single frontal facial image), which is emerging as a next-generation technology, rather than the widely used active method (requiring the person to move his or her face to prove identity). In 2022, FacePhi acquired i-Beta Level 2 certification from the National Institute of Standards and Technology (NIST), which guarantees the anti-spoofing performance of facial recognition technology. The fact that there are only nine passive i-Beta Level 2 companies in the world demonstrates that FacePhi's technology is world-class.

This investment will make Hancom the second largest shareholder of FacePhi, and the company will use it as a bridgehead to strengthen its position in the global AI market through white labeling by selling FacePhi's solutions under the Hancom brand in the Asia Pacific (APAC) region.

Hancom expects this contract to have a synergistic effect and plans to discover new and improved services and businesses by combining FacePhi's multi-recognition biometric technology with Hancom's AI, HancomWITH's security technology, Clipsoft's reporting tool, and Hancom CareLink's healthcare service.

"Through this investment, we will be able to expand Hancom's AI business area and we expect to expand overseas sales by supplying Hancom-branded FacePhi solutions to the entire Asia-Pacific region in the future," said Yeon-soo Kim, CEO of Hancom. "We will continue to lead the AI market by actively promoting collaboration with, investment in, and acquisition of competent AI businesses."

Meanwhile, the global digital authentication solution market is growing at an average annual growth rate of 12%, and as security levels are strengthened, there is a trend of shifting from the traditional fingerprint recognition-centered biometric technology to facial recognition. In order to respond to technological developments such as deepfakes, the adoption of passive methods to prevent forgery is expected to increase.

HANCOM Logo

Photo - https://mma.prnewswire.com/media/2369762/Press_Release__Hancom_s_CEO_Yeon_soo_Kim__L____FacePhi_s_CEO_Javier_Mira__R__at_the_Invest_Signing_C.jpg 
Logo - https://mma.prnewswire.com/media/2238419/4609929/HANCOM_Logo_Logo.jpg

 


These press releases may also interest you

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

at 00:00
Spectrum Dynamic's customers will...

28 avr 2024
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...



News published on and distributed by: